Biovica International AB (publ)
Research Biovica International AB (publ) (BIOVIC-B) on Bullrun: market cap SEK 130.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOVIC-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 130.78M
- Financial periodQ2 2026
- RevenueSEK 4.82M
- Net income-SEK 19.12M
- Free cash flow-SEK 16.27M
- Gross margin94.7%
Valuation Snapshot
latest market cap is SEK 130.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 9.86M | -SEK 76.47M | -SEK 71.01M | 101.0% | -0.66 | SEK 100.66M | SEK 3.04M | SEK 123.81M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 130.78M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biovica International AB (publ)'s market cap?
Biovica International AB (publ)'s market capitalization is SEK 130.78M.
What does Biovica International AB (publ) do?
Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.